Comparative Pharmacology
Head-to-head clinical analysis: DOW ISONIAZID versus MYCOBUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOW ISONIAZID versus MYCOBUTIN.
DOW-ISONIAZID vs MYCOBUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits mycolic acid synthesis in Mycobacterium tuberculosis by targeting InhA, a NADH-dependent enoyl-acyl carrier protein reductase, leading to bacterial cell wall disruption.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
300 mg orally once daily, or 5 mg/kg (max 300 mg) daily; alternatively, 15 mg/kg (max 900 mg) orally twice weekly directly observed therapy.
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
None Documented
None Documented
Fast acetylators: 0.5–2 hours (mean 1.1 h); slow acetylators: 2–5 hours (mean 3 h). Clinical context: Determines dosing interval; slow acetylators at higher risk of peripheral neuropathy.
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Renal: 75–95% (isoniazid and metabolites, primarily acetylisoniazid and isonicotinic acid); fecal <10%; biliary excretion minimal.
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Category A/B
Category C
Antimycobacterial
Antimycobacterial